Severe Acute Respiratory Syndrome (SARS)

Updated Guidelines for the Global Surveillance of SARS

August 22nd 2005

Note: * This guidance will be reviewed and revised accordingly in the event of a recurrence of a global outbreak of SARS or an outbreak of SARS in Ireland. This guidance has been updated following the WHO updated recommendations for the global surveillance of SARS October 2004. Some of this guidance is also adapted from the Health Protection Agency (HPA) (UK) and Health Canada Guidance.
# Table of Contents

Chapter 1  ................................................................................................................................. 3
Introduction

Chapter 2  .................................................................................................................................... 7
Clinical and laboratory criteria for the global surveillance of SARS

Chapter 3  .................................................................................................................................... 11
The inter-epidemic period – The SARS Alert

Chapter 4  ................................................................................................................................... 18
The global surveillance of SARS during an outbreak

Chapter 5  .................................................................................................................................... 24
International reporting of SARS

Annex 1........................................................................................................................................ 26
Summary of the essential aspects of the SARS Risk Assessment and Preparedness Framework (WHO SARS RAPF)

Annex 2........................................................................................................................................ 29
Clinical case description of SARS

Annex 3........................................................................................................................................ 31
Guidance regarding the diagnosis of SARS in the inter-epidemic period – A concern for all health-care workers (HCWs)

**Annex 4** 34
Algorithm for the Management of Returning Travellers from South-East Asia Presenting with Febrile Respiratory Illness

**Annex 5** 35
Testing for SARS in the Interepidemic Period

**Annex 6** 36
Testing for SARS during an outbreak
Chapter 1

1. Introduction
Severe Acute Respiratory Syndrome (SARS) was first recognised as a global threat in March 2003. Between March and July 2003, 8,098 probable cases of SARS were reported in 26 countries, with 774 deaths. It is likely that SARS originated in the Guangdong Province in China in November 2002. SARS is caused by a novel coronavirus known as SARS-CoV.

The natural reservoir of SARS-CoV has not been identified but a number of wildlife species – the Himalayan masked palm civet (Paguma larvata), the Chinese ferret badger (Melogale moschata) and the raccoon dog (Nyctereutes procyonoides) – consumed as delicacies in southern China have shown laboratory evidence with a related coronavirus. Domestic cats living in the Amoy Gardens apartment block in Hong Kong were also found to be infected with SARS-CoV. These findings indicate that the reservoir for this pathogen may involve a range of animal species.

The outbreak was successfully contained within five months and on July 5th 2003, the World Health Organisation (WHO) announced that the last human chain of transmission of SARS had been broken. Since July 2003, there have been four occasions when SARS reappeared. Three of these incidents were attributed to breaches in laboratory biosafety and resulted in one or more cases of SARS (Singapore, Taipei and Beijing). As a result WHO recommends that each country ensures that the correct biosafety procedures are followed by all laboratories working with the SARS coronavirus and other dangerous pathogens and that appropriate monitoring and investigation of illness in laboratory workers is undertaken. The fourth incident (Guangzhou, Guangdong province China) resulted in four sporadic, community acquired cases arising over a six week period.

In view of this, in the post outbreak period, it is imperative that all countries remain alert for the recurrence of SARS and increase their capacity to detect and respond to SARS should resurgence occur.

The updated WHO guidelines (October 2004) are aimed at the early detection and investigation of individuals with clinically apparent SARS-associated coronavirus infection i.e. symptomatic cases only. The epidemiological evidence shows that SARS-CoV is transmitted by symptomatic individuals and that asymptomatic infection poses no significant public health risk. However SARS-CoV causes a spectrum of clinical illness ranging from the severe form to milder or atypical presentations. Cases of SARS can easily escape early detection especially as acute respiratory infections account for the majority of diagnoses in adults presenting to primary care. SARS may be initially missed due to the non-specific nature of presenting symptoms, the possibility of absence of fever on initial measurements, atypical presentations, co-morbidities masking SARS and the recognised difficulties of clinically diagnosing an atypical pneumonia.

This document uses the new definitions as advised by WHO (October 2004).
1.1 Definitions

The following definitions include definitions as they apply to phases of the WHO SARS Risk Assessment and Preparedness Framework-RAPF-(See Section 1.2 and Annex 1) as well other relevant definitions related to global SARS surveillance.

**Inter-epidemic period (Phases 0-1 of the WHO SARS Risk assessment and Preparedness Framework, RAPF)**

Defined as the absence of human chains of SARS-CoV transmission worldwide,

Sporadic (isolated) cases of SARS or a common source outbreak may occur but do not result in secondary transmission.

The risk of secondary transmission of SARS-CoV has been shown to fall significantly if cases are identified and isolated within 3 days of illness onset. This requires rapid case identification, case containment and contact tracing.

**SARS cluster**

Defined as two or more epidemiologically linked “preliminary positive” and/or “probable” and/or “confirmed” cases of SARS (see Chapter 4 for case definitions).

**SARS epidemic (Phases 3-4 of the WHO SARS RAPF)**

Evidence of international spread of SARS, considered a global public health emergency.

*Note: A single exported case of SARS constitutes international spread.*

**Global interruption of SARS-CoV transmission (Phase 5 of the WHO SARS RAPF)**

Defined as twenty eight days after the last reported case of SARS globally has been placed in isolation or died AND the source(s) and route(s) of transmission have all been identified and contained.
A new (Independent) chain of human SARS transmission

A new transmission tree that cannot be linked to an existing chain of human transmission after an epidemiological investigation.

SARS-CoV infection

The term “SARS-CoV infection” is used when referring to the transmission of the SARS coronavirus and includes both symptomatic and asymptomatic infections.

Definitive laboratory testing completed

Testing meets the requirement for the laboratory diagnosis of SARS and almost always involves two or more different tests or the same assay on two or more occasions during the course of the illness or from different clinical sites.

A single test result is insufficient for the definitive diagnosis of SARS-CoV infection because both false negative and false positive results are known to occur.

Contacts

A contact is a person who is at greater risk of developing SARS because of exposure to a SARS case. Risky exposures include having cared for, lived with or having had direct contact with the respiratory secretions, body fluids and/or excretions (e.g. faeces) of cases of SARS.

Quarantine - refers to restriction of the activities of well persons who have been exposed to a case during its period of communicability.

Isolation - refers to separation, for the period of communicability, of ill i.e. symptomatic persons from others in such places and under such conditions so as to prevent or limit the direct or indirect transmission of the infectious agent.

Incubation period - refers to the time interval between infection (i.e. introduction of the infectious agent into the susceptible host) and the onset of first symptoms of illness known to be caused by the infectious agent.
### 1.2 WHO SARS Risk Assessment and Preparedness Framework-RAPF

Table 1 outlines the phases of the SARS Risk Assessment and Preparedness Framework-RAPF. *It includes both the national (Irish) and WHO preparedness phases.*

Table 1. Preparedness levels for inter-epidemic, epidemic and post-epidemic periods-National (Irish) and WHO Phases

<table>
<thead>
<tr>
<th>Who Phase</th>
<th>Action</th>
<th>Irish Phase</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 0</td>
<td>No evidence of SARS-CoV transmission to humans worldwide</td>
<td>Phase 0</td>
<td>No evidence of SARS-CoV transmission to humans worldwide</td>
</tr>
<tr>
<td>Phase 1</td>
<td>Sporadic case(s) of SARS or a common source of transmission that does not result in secondary cases.</td>
<td>Phase 1</td>
<td>Heightened threat. SARS cases in other countries with potential for spread to Ireland and UK</td>
</tr>
<tr>
<td>Phase 2</td>
<td>Confirmed human-to-human transmission. The magnitude of the outbreak is described in Phase 2, Levels 1 and 2.</td>
<td>Phase 2, Level 1</td>
<td>Heightened threat. SARS cases in other countries with potential for spread to Ireland and UK</td>
</tr>
<tr>
<td>Phase 2, Level 1</td>
<td>Chains of transmission in one location</td>
<td>Phase 2, Level 2</td>
<td>Heightened threat. SARS cases in other countries with potential for spread to Ireland and UK</td>
</tr>
<tr>
<td>Phase 2, Level 2</td>
<td>Chains of transmission in two or more locations but with no evidence of international spread</td>
<td>Phase 3</td>
<td>International spread</td>
</tr>
<tr>
<td>Phase 3</td>
<td>International spread</td>
<td>Phase 3, Level 1</td>
<td>Sporadic imported case(s) in Ireland and UK from affected areas outside UK/Ireland</td>
</tr>
<tr>
<td>Phase 3</td>
<td>International spread</td>
<td>Phase 3, Level 2</td>
<td>One or more outbreaks of SARS within a hospital and/or limited community transmission within definable groups in Ireland</td>
</tr>
<tr>
<td>Phase 3</td>
<td>International spread</td>
<td>Phase 3, Level 3</td>
<td>Outbreaks of SARS in Ireland with extensive community transmission</td>
</tr>
<tr>
<td>Phase 4</td>
<td>Slowing down of the outbreak.</td>
<td>Phase 4</td>
<td>De-escalation of the outbreak response</td>
</tr>
<tr>
<td>Phase 5</td>
<td>Global interruption of SARS-CoV transmission (epidemic halted).</td>
<td>Phase 5</td>
<td>Post –outbreak phase</td>
</tr>
</tbody>
</table>
Chapter 2 Clinical and laboratory criteria for the global surveillance of SARS

2.1 Clinical case description of SARS
The case description (see Annex 2) provides details of the spectrum of disease including atypical presentations, the clinical evolution of SARS, and radiological and laboratory findings to assist clinicians with their diagnosis. All health-care workers should be aware of the clinical symptoms and signs of SARS and the appropriate transmission-based precautions that should be applied (see Annex 3).

2.2 The differential diagnosis of SARS
The clinical symptoms and signs of disease caused by SARS-CoV are non-specific. The differential diagnosis therefore may include a range of common respiratory pathogens including influenza virus, parainfluenza viruses, respiratory syncytial virus (RSV), *Haemophilus influenzae*, *Mycoplasma pneumoniae*, *Chlamydia* species, *Legionella* species, and *Coxiella burnetii*. In addition, there are currently no laboratory tests that reliably diagnose SARS in the first few days of illness. Other human coronaviruses (e.g. OC43 and 229E) and animal coronaviruses can also cause diagnostic confusion.

Clinical algorithms incorporating clinical and epidemiological criteria can assist in the systematic assessment of patients presenting with an ARI, particularly when linked to testing algorithms using the panel of common respiratory pathogens (See Annex 4-SARS and Avian Influenza algorithm May 2004).

2.3 Investigation of a patient with a differential diagnosis of SARS
Caution should be exercised in diagnosing non-specific viral pneumonia without detailed inquiry to ascertain risk factors for SARS in the 10 days before the onset of illness. These include:

1. Determining whether other family members and/or other close social or occupational contacts have had a similar illness (particularly in a laboratory or hospital setting), OR
2. A relevant history of travel to an area at risk of SARS-CoV transmission from animal reservoirs or a recent outbreak of SARS.

If person with severe unexplained pneumonia answers yes to at least one of the above, the clinician should inform relevant staff in the hospital and also notify the regional department of public health to make them aware of the situation in case it progresses to a SARS alert. The regional department of public health will inform the Health Protection Surveillance Centre (HPSC) so that enhanced surveillance procedures can be instituted nationally and WHO informed as appropriate.
Clinicians in consultation with consultant microbiologists/virologists, infectious disease physicians and specialists in public health medicine should consider testing for SARS-CoV if no alternative diagnosis is found in 72 hours.

**NOTE:** In the post outbreak period, when the prevalence of SARS is low, the positive predictive value (PPV) of the SARS Co-V test is low i.e. when SARS has a 1% prevalence in the population, the PPV is 9% compared to a PPV of 95% with a 50% prevalence. The sensitivity of detecting SARS in clinical specimen is 50% and the specificity is 95%.

Establishing an alternative diagnosis should not delay the triggering of a SARS Alert (see section 3) and the timely implementation of patient isolation and stringent infection control measures if a SARS diagnosis cannot be confidently excluded. Indications for testing during a SARS Alert are given in section 3.4.

**2.4 The laboratory diagnosis of SARS**

The following tests are recommended for the laboratory diagnosis of SARS. **A single test result is insufficient for the definitive diagnosis of SARS-CoV infection because both false negative and false positive results are known to occur** (see below, "The interpretation of laboratory results for SARS-CoV").

### Nucleic acid tests

Reverse transcription polymerase chain reaction (RT-PCR), positive for SARS-CoV using a validated method from:

1. At least two different clinical specimens (e.g. nasopharyngeal and stool)

OR

2. The same clinical specimen collected on two or more occasions during the course of the illness (e.g. sequential nasopharyngeal aspirates)

OR

3. Two different assays or repeat RT-PCR using a new RNA extract from the original clinical sample on each occasion of testing.

### Seroconversion by ELISA or IFA

- Negative antibody test on acute state serum followed by positive antibody test on convalescent phase serum tested in parallel.

OR

- Fourfold or greater rise in antibody titre between acute and convalescent phase sera tested in parallel.

**Note:** Virus neutralization should be conducted to exclude serological cross-reactions with other human and/or animal coronaviruses. Virus neutralization should only be conducted in a specialized laboratory under the appropriate biosafety level (BSL3). It is recommended in the inter-epidemic period and for at least one case in each new (independent) chain of human transmission when an outbreak is being verified to exclude serological cross-reactions. Once SARS-CoV transmission is well established, virus...
neutralization will not usually be required but may be used when the results of RT-PCR and serology are difficult to interpret.

**Virus isolation**
Isolation in cell culture from any clinical specimen and identification of SARS-CoV using a validated method such as RT-PCR.

**The interpretation of laboratory results for SARS-CoV**
The reliability of the results of diagnostic tests for SARS-CoV infection depends crucially on (a) the type of clinical specimens collected, (b) the time of collection and the (c) method of collection. WHO has established a network of international reference and verification laboratories for SARS to assist with independent verification of testing in national laboratories and for primary diagnosis if requested. Guidance on the clinical specimens for the laboratory diagnosis of SARS-CoV and the timing of their collection can be found in *WHO SARS International Reference and Verification Laboratory Network: Policy and Procedures in the Inter-epidemic Period.* ([http://www.who.int/csr/sars/guidelines/en/WHOSARSReferencelab.pdf](http://www.who.int/csr/sars/guidelines/en/WHOSARSReferencelab.pdf)).

Serological testing is improving, although quality assurance has indicated a significant level of missed positive specimens and of false positive results. Where acute and convalescent phase sera show a fourfold or greater rise in titre when tests are carried out in parallel, but no PCR product is available or virus isolated, viral neutralization assays should be performed.

This test should be performed by the national reference laboratory and, depending on whether the case occurs in the inter-epidemic period or during an outbreak, by a WHO SARS International Reference and Verification Laboratory for final confirmation and to ensure that the rising titre is not due to a second human coronavirus. In the inter-epidemic period, WHO strongly recommends that all countries seek verification of laboratory-confirmed cases of SARS ("preliminary positive" cases), preferably by an external laboratory, which is part of the WHO SARS International Reference and Verification Laboratory Network.

2.5 Clinical evidence for SARS

The following clinical criteria for SARS, presented in Table 2, are used for public health (surveillance) purposes only. Clinicians are advised to refer to the clinical case description for further details of the symptoms and signs of SARS (Annex 2).

Table 2. Clinical evidence for SARS for surveillance purposes

<table>
<thead>
<tr>
<th>Clinical evidence for SARS</th>
</tr>
</thead>
<tbody>
<tr>
<td>A clinical case of SARS is an individual with:</td>
</tr>
<tr>
<td>1. A history of fever, or documented fever $\geq 38$ °C (100.4 °F).</td>
</tr>
<tr>
<td><strong>AND</strong></td>
</tr>
<tr>
<td>2. One or more symptoms of lower respiratory tract illness (cough, difficulty breathing, shortness of breath)</td>
</tr>
<tr>
<td><strong>AND</strong></td>
</tr>
<tr>
<td>3. Radiographic evidence of lung infiltrates consistent with pneumonia or ARDS or autopsy findings consistent with the pathology of pneumonia or ARDS without an identifiable cause.</td>
</tr>
<tr>
<td><strong>AND</strong></td>
</tr>
<tr>
<td>4. No alternative diagnosis can fully explain the illness.</td>
</tr>
</tbody>
</table>

2.6 Laboratory case definition for SARS

An individual who tests positive for SARS-CoV by any of the testing procedures described above in section 2.4 using validated testing methods and appropriate quality assurance mechanisms, including positive and negative controls. See section 4.1 for further details of how "laboratory confirmation" is interpreted in the interepidemic period and once human transmission of SARS has been established.
Chapter 3. The inter-epidemic period – The SARS Alert

3.1 Objectives of the SARS Alert

1. Provide early warning of the potential recurrence of SARS to:
   - Rapidly implement appropriate infection control measures in a health-care setting
   - Expedite diagnosis
   - Activate the public health response
2. Raise a global alert if indicated.

3.2 Definition of the SARS Alert

Table 3. The SARS Alert

<table>
<thead>
<tr>
<th></th>
<th>An individual with clinical evidence of SARS AND with one or more of the following epidemiological risk factors for SARS-CoV infection in the 10 days before the onset of symptoms:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Employed in an occupation associated with an increased risk of SARS-CoV exposure (e.g. staff in a laboratory working with live SARS-CoV/SARS-CoV-like viruses or storing clinical specimens infected with SARS-CoV; persons with exposure to wildlife or other animals considered a reservoir of SARS-CoV, their excretions or secretions, etc).</td>
</tr>
<tr>
<td></td>
<td>Close contact (having cared for, lived with, or had direct contact with the respiratory secretions or body fluids) of a person under investigation for SARS.</td>
</tr>
<tr>
<td></td>
<td>History of travel to, or residence in, an area experiencing an outbreak of SARS (See also Note 5 Page 13)</td>
</tr>
</tbody>
</table>

OR

| 2 | Two or more health-care workers with clinical evidence of SARS in the same health-care unit and with onset of illness in the same 10-day period. |

OR

| 3 | Three or more persons (health-care workers and/or patients and/or visitors) with clinical evidence of SARS with onset of illness in the same 10-day period and epidemiologically linked to a health-care facility. |
Notes

1 In the context of a SARS Alert, the term “health-care worker” includes ALL hospital staff.

2 The definition of the health care unit in which the cluster occurs will depend on the local situation. Unit size may range from an entire health care facility if small, to a single department or ward of a large tertiary hospital.

3 All laboratories that propagate SARS-CoV/SARS-CoV-like viruses, or use clinical materials from SARS patients or infected animals, infectious clones and/or replicons should implement a health monitoring programme for staff.

4 Personnel with an occupational risk of SARS should be informed of their responsibility to volunteer details of their occupational history when seeking health care for an acute febrile illness.

5 It is important that clinicians ask patients about risk factors for SARS if they present with a clinically compatible illness. This includes determining whether other family members and/or close social or occupational contacts (particularly in a laboratory or hospital setting) have had a similar illness, or a relevant history of travel to an area at risk of SARS-CoV transmission from animal reservoirs or a recent outbreak of SARS.

In order to detect a cluster of SARS in the healthcare setting, clinicians are asked to notify cases of unexplained pneumonia in healthcare workers to the Medical Officer of Health (Director of Public Health). All healthcare workers should be asked to inform the Occupational Health Physician/Department if they develop signs of severe pneumonia that requires hospital admission

Following the last reported case in an outbreak of SARS, an individual fulfilling the clinical case definition for SARS should be asked about travel to the outbreak area(s) in the preceding 28 days before illness onset. The period for heightened vigilance for SARS has been extended to 28 days after the last reported case of SARS globally has been placed in isolation or died and the source(s) and route(s) of transmission have been all identified and contained.

The extended period of vigilance for SARS after an outbreak arises from lessons learned during the 2002-2003 epidemic and is recommended to reduce the risk of ongoing transmission arising from missed SARS Co-V infection and from prematurely stepping down respiratory precautions.

3.3 Assessing the risk of the emergence or introduction of SARS-like coronaviruses during the inter-epidemic period

Three of the four SARS incidents since July 2003 have been attributed to breaches in laboratory biosafety. WHO strongly recommends Biosafety Level 3 (BSL3) as the minimum containment level to work with live SARS-CoV. WHO also urges countries to maintain a thorough inventory of laboratories working with and/or storing live SARS coronavirus and to ensure that necessary biosafety standards are in place.

WHO has defined three risk categories (see Table 4) that take into account the experience during the 2002–2003 SARS epidemic and the potential for emergence of SARS-CoV.
### Table 4. Risk categories for the emergence of SARS

<table>
<thead>
<tr>
<th>Risk Category</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergence of SARS-CoV-like viruses from wildlife or other animal reservoirs</td>
<td>Countries/areas identified as source(s) of the epidemic in 2002–2003 in southern China or areas with an increased likelihood of animal-to-human transmission of SARS-CoV-like viruses from wildlife or other animal reservoirs.</td>
</tr>
</tbody>
</table>
| Emergence or introduction of SARS-CoV from laboratories or international travel | Countries/areas at potentially higher risk of SARS-CoV emergence or introduction due to the presence of laboratories in which SARS-CoV and/or SARS-CoV-like viruses are being studied or in which clinical specimens infected with SARS-CoV are being processed or stored.  
  OR  
  Countries/areas with entry of large numbers of persons from areas in which wildlife or other animal reservoirs of SARS-CoV-like viruses are found. |
| Low risk of SARS-CoV emergence or Introduction                              | Countries/areas that never reported cases or reported only imported cases during the 2002-2003 epidemic, and that do not conduct research using live SARS-CoV-like viruses or store clinical samples from SARS cases. |

*Note:* Some countries/areas may fall into two risk categories.

### 3.4 Indications for testing for SARS-CoV in the interepidemic period

The risk of false positive results from SARS-CoV testing will be high in the inter-epidemic period given the limitations of currently available laboratory tests and without any evidence that the virus is circulating in human populations. In addition, other common respiratory infections causing pneumonia or Acute Respiratory Distress Syndrome (ARDS) may stimulate testing for SARS-CoV. Experience from the 2002–2003 SARS epidemic and the four SARS incidents since July 2003 indicates that certain human and animal populations are at higher risk of infection and disease from SARS-CoV and SARS-CoV-like viruses (see section 3.7).
Confidence in the accuracy of a positive or negative test result will vary with the risk that SARS-CoV is present in different settings, i.e. the predictive value of the test varies with changes in the prevalence of the aetiologic agent/disease. WHO recommends that clinicians, epidemiologists, public health and laboratory experts consult together on persons under investigation for SARS in the inter-epidemic period. In low risk settings where false positive results for SARS-CoV are most likely, the triage process should ensure that testing for SARS-CoV is considered in the context of clinical and epidemiological evidence that the virus may be the etiological agent causing an individual case or cluster of cases of Acute Respiratory Infection (ARI). Such an approach will help to limit the inappropriate use of resources and the risk of overwhelming the health system by unnecessary activation of hospital-based and public health SARS responses.

Thus, WHO recommends testing in the situations described in Table 5.

### Table 5. Risk of SARS emergence and indications for testing

<table>
<thead>
<tr>
<th>Risk Category</th>
<th>Indications for Testing</th>
</tr>
</thead>
</table>
| Emergence of SARS-CoV-like viruses from wildlife or other animal reservoirs | In the investigation of a SARS Alert  
As part of enhanced surveillance for SARS in populations at risk  
As part of special studies for evidence for SARS-CoV-like viruses in wildlife and other animal reservoirs |
| Emergence or introduction of SARS-CoV from laboratories or international travel | In the investigation of a SARS Alert  
As part of enhanced surveillance for SARS in human populations at risk |
| Low risk of SARS-CoV emergence or introduction           | In the investigation of a SARS Alert |

### 3.5 Public health management of a SARS Alert

#### Public health actions when a SARS Alert is raised

1. Patient(s) should be immediately isolated and transmission-based precautions instituted, if not already in place (35).
2. The diagnosis should be expedited.
3. Contacts of persons under investigation for SARS should be traced and placed on twice daily fever monitoring until SARS has been ruled out as the cause of the illness.-This refers to all those defined by SARS Alert Table 3.
   a. Note however, definition one outlines the epidemiological risk factors for SARS-CoV in the 10 days prior to the onset of symptoms. These include those employed in an occupation associated with an increased risk of SARS-CoV exposure, close contact with a person under investigation for SARS and history of travel or residence in an area experiencing a SARS outbreak. These
persons should be considered a “Person under Investigation” as outlined in Section 4.1.
b. The reference to travel to a country with a SARS outbreak (rather than travel to an area of possible re-emergence—for management of this situation see, Point 1 in Notes below) explains the need for more rigorous tracing and follow-up of contacts prior to a SARS test being undertaken or diagnosis being confirmed.

4. All contacts should ideally be given written information on: the clinical picture, transmission and other features associated with SARS, and information on respiratory hygiene and contact precautions.

NOTES

1. Possible cases arising from a history of travel to an area of possible re-emergence not currently experiencing an outbreak of SARS are unlikely in the interepidemic period to turn out to be true cases. Therefore no contact tracing is undertaken until results of SARS-CoV test are available (which will be done if deemed appropriate after 72 hours as outlined above)—See Annex 4—Algorithm for the Management of Returning Travellers from South-East Asia presenting with Febrile Respiratory Illness

2. If the results are negative for SARS-CoV and alternative diagnosis made, no contact tracing is required. If no alternative diagnosis made and illness compatible with SARS consult with HPSC.

3. If the results are positive for SARS-CoV, then person will either be a probable or confirmed case of SARS and guidelines for contact tracing and management of close contacts of such cases are outlined in Section 2.6. Interim Guidelines for healthcare professional document, February 2004.

Management of contacts within a health-care setting following a SARS Alert

1. Inpatient contacts should be isolated or cohorted away from unexposed patients and transmission-based precautions instituted. They should be placed on active fever surveillance.

2. Exposed staff should be placed on active fever surveillance, and following a risk assessment, should either be (a) cohorted to care for exposed patients (“work quarantine”) or (b) redeployed to non-clinical duties depending on local circumstances.

Management of community contacts following a SARS Alert

Community contacts should:

1. Be informed that the most consistent first symptom that is likely to appear is fever and instructed on how to self-monitor for fever. Fever monitoring should be performed twice daily for 10 days from the last contact with a person under investigation for SARS.
2. Should report the onset of fever and/or other symptoms to health authorities immediately and place themselves in isolation pending medical care.
3. Be visited or telephoned daily by a member of the public health-care team to ascertain their clinical status.
4. Be investigated locally at an appropriate health-care facility if they develop symptoms. Informing the health-care facility before presenting for medical care will minimize the risk of nosocomial transmission.

**Reporting to WHO**
1. National public health authorities should report every laboratory-confirmed case of SARS to WHO.
2. However, in view of the global attention given to SARS rumours, informing WHO of clusters of acute respiratory disease and/or high-risk individuals under investigation for SARS will facilitate rapid verification and the accurate dissemination of information to other governments, the media and the public.

**3.6 Indicators of the quality of the SARS Alert Mechanism**

WHO recommends that national public health authorities monitor the quality of the SARS alert mechanism, e.g. by establishing indicators based on:

1. The number of alerts expected and reported by health facilities over time
2. The time taken to implement transmission-based precautions and expedite diagnosis
3. The time taken to alert local public health authorities, national public health authorities
4. The time taken to complete contact tracing and quarantine contacts.
5. This list is not meant to be exhaustive but rather a suggested approach to monitoring the alert mechanism.

**3.7 Enhanced surveillance and special studies in human and animal populations at higher risk of SARS-CoV infections during a SARS Alert**

If a patient is admitted with a clinical diagnosis of SARS, the infection control team in the hospital should:

1) Be alert for clusters of pneumonia among healthcare workers (HCWs)
2) **If there is evidence of transmission of SARS in the hospital setting, the following should be undertaken:**
   a. Monitor HCWs taking care of SARS patients for daily temperature readings, cough or shortness of breath
   b. Screen all visitors for fever, cough, shortness of breath and SARS risk factors outlined above
   c. Monitor HCWs and inpatients on a daily basis for fever, cough, shortness of breath and SARS risk factors
3) Other enhanced surveillance to be considered.
While the following list outlining enhanced surveillance activities is not applicable in the interepidemic period to a low risk country like Ireland consideration should be given to the list in the context of planning how enhanced surveillance marked with an asterisk would operate during an outbreak of SARS in this country.

a) Fever surveillance of occupational risk groups e.g. laboratory workers in the interepidemic period.*
b) Surveillance for pneumonia in settings such as nursing homes, rehabilitation units, community health care centres and in private practice.*
c) Surveillance of persons discharged from hospital with a diagnosis of unspecified atypical pneumonia during and following an outbreak of SARS.*
d) Surveillance for absenteeism among health care workers caring for patients with SARS and laboratory staff working with SARS-CoV and products of experimental work on SARS-CoV or potentially infected clinical materials.*
e) Surveillance for requests for laboratory testing for SARS-CoV.*
f) Surveillance for unexplained deaths following an acute respiratory illness.*
g) Serological and clinical surveillance of high risk populations (health care workers, laboratory staff working with SARS-CoV or in laboratories storing clinical samples infected with SARS-CoV, etc.).*
4. The global surveillance of SARS during an outbreak

4.1 Surveillance case definitions for SARS

Section 4.1 outlines surveillance case definitions, 1 to 7 for SARS. Only individuals fulfilling one of the surveillance case definitions from 1 to 5 should be officially reported to WHO.

**Note:** National public health authorities may choose to use additional operational categories e.g. "persons under investigation for SARS" or "suspect" cases, as seen in 6 and 7 before the definitive results of testing are available.

Table 6. Surveillance case definitions for SARS during an outbreak

<table>
<thead>
<tr>
<th>Case Definition</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Preliminary positive case of SARS</td>
<td>An individual with clinical evidence for SARS AND who meets the laboratory case definition of SARS-CoV infection where testing has only been performed at a national reference laboratory.</td>
</tr>
<tr>
<td>2. Confirmed case of SARS</td>
<td>A &quot;preliminary positive&quot; case of SARS where at least one case in the first chain of transmission identified in the country/area has been independently verified by a WHO International SARS Reference and Verification Laboratory.</td>
</tr>
<tr>
<td></td>
<td>OR An individual with clinical and epidemiological evidence* for SARS AND with preliminary laboratory evidence of SARS-CoV infection based on the following tests performed at a national reference laboratory or a designated sub-national laboratory:</td>
</tr>
<tr>
<td></td>
<td>a) A single positive antibody test for SARS-CoV</td>
</tr>
<tr>
<td></td>
<td>OR b) A positive PCR result for SARS-CoV on a single clinical specimen and assay.</td>
</tr>
<tr>
<td>OR</td>
<td>A &quot;preliminary positive&quot; case of SARS where testing performed at a national reference laboratory has been independently verified by a WHO International SARS Reference and Verification Laboratory.</td>
</tr>
<tr>
<td>3. Probable case of SARS</td>
<td>An individual with clinical evidence of SARS epidemiologically linked to a ‘preliminary positive’ or ‘confirmed’ case of SARS.</td>
</tr>
<tr>
<td>OR</td>
<td>An ‘unverifiable’ case of SARS if epidemiologically linked to a ‘preliminary positive’ or ‘confirmed’ case.</td>
</tr>
</tbody>
</table>

---

*Epidemiological evidence for SARS is linkage to a chain of human transmission where at least one case in the first chain of transmission identified in the country area has been independently verified by a WHO International SARS Reference and Verification Laboratory*
## 4. Unverifiable case of SARS

<table>
<thead>
<tr>
<th>An individual with clinical evidence of SARS but in whom initial laboratory results are negative, if done, and the patient is lost to follow up.</th>
</tr>
</thead>
<tbody>
<tr>
<td>OR</td>
</tr>
<tr>
<td>A deceased individual with a pre-morbid history of illness compatible with SARS AND</td>
</tr>
<tr>
<td>a) whose autopsy findings are consistent with the pathology of pneumonia or ARDS but in whom SARS-CoV testing was not done or was incomplete</td>
</tr>
<tr>
<td>OR</td>
</tr>
<tr>
<td>b) in whom neither an autopsy nor laboratory testing were performed.</td>
</tr>
</tbody>
</table>

### Notes:
- One or more cases in the first chain of human transmission occurring in countries/areas previously free of SARS should be independently verified by a WHO International SARS Reference and Verification Laboratory.
- In the event of a large outbreak where sub-national laboratories may be designated to perform SARS testing by the national health authority, WHO recommends that at least one case in all subsequent new (independent) chains of transmission should be independently verified by a National SARS reference laboratory.

The following case definitions (5 and 6) apply in Ireland ONLY to the surveillance of SARS in the presence of known transmission (person-to-person) worldwide.

## 5. Person Under Investigation

<table>
<thead>
<tr>
<th>A person presenting with either:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever (over 38 degrees Celsius)</td>
</tr>
<tr>
<td>OR</td>
</tr>
<tr>
<td>Respiratory Symptoms (cough or breathing difficulties)</td>
</tr>
</tbody>
</table>

### AND

One or more of the following exposures during the 10 days prior to the onset of symptoms:

- Close contact* with a person who is a preliminary positive, unverifiable, probable or confirmed case
- Recent travel to a foreign or domestic location with recent local transmission of SARS

Recent travel or visit to an identified setting where exposure to SARS may have occurred (e.g. hospital [including any hospital with an occupied SARS unit], household, workplace, school, etc.).**

### AND

No other known cause of current illness

*Close contact means having cared for, lived with or had face-to-face (within 1 metre) contact with, or having had direct contact with respiratory secretions and/or body fluids of a person with SARS.
** This includes inpatients, employees or visitors to an institution if the exposure setting is an institution
6. Suspect case (SARS alert)

An individual with clinical evidence of SARS (see below “clinical evidence for SARS”) AND

with one or more of the following epidemiological risk factors for SARS-CoV infection in the 10 days before the onset of symptoms:

- Employed in an occupation associated with an increased risk of SARS-CoV exposure (e.g. staff in a laboratory working with live SARS-CoV/SARS-CoV-like viruses or storing clinical specimens infected with SARS-CoV; persons with exposure to wildlife or other animals considered a reservoir of SARS-CoV, their excretions or secretions, etc.).

- Close contact\(^1\) of a person under investigation for SARS.

- History of travel\(^2\) to, or residence in, an area experiencing an outbreak of SARS.

OR

Two or more health-care workers\(^3\) with clinical evidence of SARS in the same health-care unit and with onset of illness in the same 10-day period.

OR

Three or more persons (health-care workers and/or patients and/or visitors) with clinical evidence of SARS with onset of illness in the same 10-day period and epidemiologically linked to a health-care facility.

---

\(^1\) A contact is a person who is at greater risk of developing SARS because of exposure to a SARS case. Risky exposures include having cared for, lived with, or having had direct contact with the respiratory secretions, body fluids and/or excretions (e.g. faeces) of cases of SARS.

\(^2\) Following the last reported case in an outbreak of SARS, an individual fulfilling the clinical case definition for SARS should be asked about travel to the outbreak area(s) in the preceding 28 days before illness onset.

\(^3\) In the context of a SARS Alert, the term “health-care worker” includes ALL hospital staff. The definition of the health care unit in which the cluster occurs will depend on the local situation. Unit size may range from an entire health care facility if small, to a single department or ward of a large tertiary hospital.
Clinical evidence for SARS

The following clinical description for SARS and has been developed for public health purposes.

A clinical case of SARS is an individual with:

A history of fever, or documented fever $\geq 38 \, ^\circ\text{C}$ ($100.4 \, ^\circ\text{F}$).

AND

One or more symptoms of lower respiratory tract illness (cough, difficulty breathing, shortness of breath)

AND

Radiographic evidence of lung infiltrates consistent with pneumonia or acute respiratory distress syndrome (ARDS) or autopsy findings consistent with the pathology of pneumonia or ARDS without an identifiable cause.

AND

No alternative diagnosis can fully explain the illness.

It is important that clinicians obtain a detailed travel history from patients with symptoms and signs consistent with clinical SARS as well as ascertain whether other family members and/or close contacts (particularly within the hospital setting) have had a similar illness within the 10 days prior to the patient’s onset of illness.

4.2 Verifying an outbreak of SARS

During the inter-epidemic period, WHO will utilize highly specific laboratory criteria for the diagnosis of SARS and requests independent verification at one or more WHO International SARS Reference and Verification Network laboratories to reduce the risk of false positive and false negative test results. The laboratory requirements for confirmation imply the use of validated testing methods and appropriate quality assurance mechanisms, including positive and negative controls in all laboratories undertaking diagnostic and reference work for SARS.

Once an outbreak of SARS has been independently verified, the laboratory requirements for case confirmation will be less specific than those recommended for the inter-epidemic period. National health authorities may wish to devolve laboratory testing to sub-national laboratories which meet the quality standards described above. WHO also advises that during a sustained outbreak of SARS, countries test a proportion of individuals with clinical evidence for SARS throughout the outbreak as a form of quality assurance. Such
testing is recommended to reduce diagnostic confusion with other infectious conditions that mimic SARS clinically, especially as the epidemic wanes.

Table 7 summarises the indications for independent verification of positive tests performed at national reference laboratories.

**Table 7. Indications for the independent verification of positive SARS tests by a WHO International SARS Reference and Verification Network laboratory**

<table>
<thead>
<tr>
<th>In the inter-epidemic period</th>
</tr>
</thead>
<tbody>
<tr>
<td>All sporadic ‘preliminary positive’ cases.</td>
</tr>
<tr>
<td>At least one case in each new (independent) chain of human transmission.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>During an outbreak or global epidemic of SARS</th>
</tr>
</thead>
<tbody>
<tr>
<td>At least one case in the first chain of human transmission occurring in countries previously free of SARS, and depending on the size of the country, in areas within countries previously free of SARS.</td>
</tr>
<tr>
<td><strong>Note:</strong> In the event of a large outbreak where sub-national laboratories may be designated to perform SARS testing by the national health authority, WHO recommends that at least one case in all subsequent new (independent) chains of transmission should be independently verified by a national SARS reference laboratory.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>At any time</th>
</tr>
</thead>
<tbody>
<tr>
<td>In the event of a change in the clinical spectrum of the disease, or when clinical and/or epidemiological evidence suggests increased virulence or that the virus is more readily transmissible or is spreading by previously unknown or uncommon route(s) of transmission.</td>
</tr>
</tbody>
</table>

A higher level of global vigilance, and lower threshold for SARS testing, will be required during another epidemic of SARS. The risk of false positive results from SARS-CoV testing will be lower than during the inter-epidemic period. However, experience during the 2002–2003 epidemic suggests that in areas free of SARS the positive predictive value of clinical and epidemiological evidence for SARS will remain low when assessed against laboratory tests. Annexes 5 and 6 present diagnostic and reporting algorithms for SARS in the inter-epidemic and epidemic periods respectively.

**4.3 Reclassification of SARS cases and exclusion criteria**

a) A "preliminary positive" case of SARS will be reclassified as a "confirmed case" of SARS under the circumstances described in section 4.1.

b) An individual with clinical and epidemiological evidence for SARS AND with preliminary laboratory evidence of SARS-CoV infection will be reclassified as a "confirmed case" of SARS under the circumstances described in section 4.1.

c) An "unverifiable" case of SARS will be classified as a "probable case" if epidemiologically linked to a "preliminary positive" or "confirmed" case of SARS.
d) National public health authorities should not downgrade or discard individuals as cases while awaiting the results of laboratory tests or on the basis of a single negative result if clinical and/or epidemiological evidence supports the diagnosis.

e) A person under investigation for SARS should be discarded as a case if an alternative diagnosis can fully explain the illness OR a validated serological test conducted under appropriate quality assurance mechanisms, including positive and negative controls is negative 28 days or more after the onset of symptoms.
5. International reporting of SARS

5.1 WHO global surveillance for SARS
For the purposes of the international reporting of SARS to WHO, national public health authorities are requested to officially report:

- "preliminary positive" cases
- "probable" cases
- "confirmed" cases
- "unverifiable" cases during an outbreak of SARS.

National health authorities should report the first "preliminary positive" case(s) of SARS in their country to WHO within 24 hours of the receipt of positive test results from their national SARS reference laboratory. However, in view of the global attention given to SARS rumours, informing WHO of clusters of acute respiratory disease and/or high-risk individuals under investigation for SARS will facilitate rapid verification and the accurate dissemination of information to other governments, the media and the public. See also the WHO SARS Risk Assessment and Preparedness Framework (Annex 1).

Reporting to WHO should continue to exclude asymptomatic SARS-CoV infections, and individuals with clinically compatible illness but without laboratory confirmation unless the latter are part of a laboratory-confirmed chain of human transmission (i.e. fulfil the "probable case" definition, see section 4.1).

No nil reporting is required

WHO requests that national health authorities inform the focal points at the WHO Country Office, Regional Offices or Headquarters of every person meeting WHO definitions of preliminary positive, probable or laboratory-confirmed cases of SARS within 24 hours of the receipt of the positive test results for SARS-CoV infection. This will allow WHO to assess the need for a global alert for SARS on the basis of that notification as appropriate.

In the event of an international traveller being investigated for SARS, all national public health authorities involved in international contact tracing around the case(s) should communicate directly with each other during the investigation. WHO will remain informed on the progress of the investigation and assist as required. Confirmation of the international spread of SARS is a global public health emergency (Phases 3–4 of the WHO SARS RAPF).
WHO will continue to identify and verify rumours of events of international public health concern, including rumours about SARS, through its usual well-established mechanisms.

5.2 The minimum global dataset

WHO is developing an expanded minimum global dataset, data dictionary and reporting format for the inter-epidemic period and for reporting during another outbreak of SARS should it occur. The aim of the minimum global dataset is to systematically collect the clinical, laboratory and epidemiological data required to refine estimates of the key distributions for SARS (incubation period, period of communicability, case fatality ratios and basic reproduction number, R0) as well as improving our knowledge of the risk factors for SARS-CoV infection, the spectrum of disease it causes, and aid in the evaluation of control measures.

This document will be posted on the WHO SARS web site when available.
Annex 1. Summary of the essential aspects of the SARS Risk Assessment and Preparedness Framework (WHO SARS RAPF)

Aims and objectives of the WHO SARS Risk Assessment and Preparedness Framework

The Framework was developed as an aid to national health authorities for the detection and public health management of SARS. The document:

1) Outlines different scenarios that might occur at sequential phases of a SARS outbreak.
2) Assigns a level of risk as an outbreak occurs or escalates at each phase.
3) Suggests activities that areas with local transmission of SARS, SARS-free areas and WHO should undertake.
4) Recommends surveillance activities to be established or strengthened as part of national preparedness planning.

Phases of the WHO SARS Risk Assessment and Preparedness Framework

In the assessment framework, the ‘phase’ refers to sequential stages that might be seen in a SARS outbreak and the recommended public health response. The phases are defined in Table A1.1. The detailed description of the recommended public health actions is found in the WHO SARS RAPF document. National public health authorities are encouraged to link their own SARS contingency plans (either existing or future) to the global framework. Phases 0-1 correspond to the absence of human chains of SARS-CoV transmission worldwide. In these phases, WHO and national health authorities should direct efforts towards assessing preparedness and developing contingency plans. It is possible to move from one phase to another in a non-sequential fashion during an outbreak of SARS; for example, laboratory confirmation of SARS in a cluster of cases of acute respiratory illness would result in a shift from Phase 0 directly to Phase 2. The escalation or stepping down of public health activities in response to a phase shift is described in the WHO SARS RAPF.

Evaluation of risk

It is important to recognize that the Framework only aims to provide guidance. Many situations will require a risk assessment of the specific circumstances. For example, the stage of illness at which an individual presents, the number of contacts identified, cluster size, the route(s) of transmission and the transmission setting (hospital or community) are all important risk factors for transmission and ease of containment. Similar situations may present different risks in different settings due to factors that include:

1) The relative strength of acute medical and public health infrastructure, especially surveillance and response capacity.
2) The level of preparedness, including whether a country has experience in dealing with SARS and whether an appropriate legal framework exists that facilitates the containment of epidemic prone diseases.
3) The geographical location, including the risk of SARS-CoV emergence or re-emergence, the mobility of local populations and whether the site is an international hub for travel or trade. See section 3.3 for the assessment of risk of the re-emergence of SARS-like coronaviruses in the inter-epidemic period.
<table>
<thead>
<tr>
<th>Who Phase</th>
<th>Action</th>
<th>Irish Phase</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 0</td>
<td>No evidence of SARS-CoV transmission to humans worldwide</td>
<td>Phase 0</td>
<td>No evidence of SARS-CoV transmission to humans worldwide</td>
</tr>
<tr>
<td>Phase 1</td>
<td>Sporadic case(s) of SARS or a common source of transmission that does not result in secondary cases.</td>
<td>Phase 1</td>
<td>Heightened threat. SARS cases in other countries with potential for spread to Ireland and UK</td>
</tr>
<tr>
<td>Phase 2</td>
<td>Confirmed human-to-human transmission. The magnitude of the outbreak is described in Phase 2, Levels 1 and 2.</td>
<td>Phase 1 Level 1</td>
<td>Heightened threat. SARS cases in other countries with potential for spread to Ireland and UK</td>
</tr>
<tr>
<td>Phase 2, Level 1</td>
<td>Chains of transmission in one location</td>
<td>Phase 2 Level 1</td>
<td>Heightened threat. SARS cases in other countries with potential for spread to Ireland and UK</td>
</tr>
<tr>
<td>Phase 2, Level 2</td>
<td>Chains of transmission in two or more locations but with no evidence of international spread</td>
<td>Phase 2 Level 2</td>
<td>Heightened threat. SARS cases in other countries with potential for spread to Ireland and UK</td>
</tr>
<tr>
<td>Phase 3</td>
<td>International spread</td>
<td>Phase 3 Level 1</td>
<td>Sporadic imported case(s) in Ireland and UK from affected areas outside UK/Ireland</td>
</tr>
<tr>
<td>Phase 3</td>
<td>International spread</td>
<td>Phase 3 Level 2</td>
<td>One or more outbreaks of SARS within a hospital and/or limited community transmission within definable groups in Ireland</td>
</tr>
<tr>
<td>Phase 3</td>
<td>International spread</td>
<td>Phase 3 Level 3</td>
<td>Outbreaks of SARS in Ireland with extensive community transmission</td>
</tr>
<tr>
<td>Phase 4</td>
<td>Slowing down of the outbreak.</td>
<td>Phase 4</td>
<td>De-escalation of the outbreak response</td>
</tr>
<tr>
<td>Phase 5</td>
<td>Global interruption of SARS-CoV transmission (epidemic halted).</td>
<td>Phase 5</td>
<td>Post–outbreak phase</td>
</tr>
</tbody>
</table>
Annex 2. Clinical case description of SARS

**Aetiology**
Severe acute respiratory syndrome (SARS) is a disease caused by the SARS coronavirus (SARS-CoV).

**Epidemiology**
Nosocomial transmission of SARS-CoV has been a striking feature of the SARS outbreak. The majority of the cases are adults. Children are less commonly affected than adults and usually have a milder illness\(^1\). The mean incubation period is 5 days with the range of 2–10 days although there are isolated reports of longer incubation periods. Cases outside the 2 to 10 day incubation period have not necessarily been subjected to rigorous and standardized investigation, including serological confirmation. There have been no reports of transmission occurring before the onset of symptoms.

**Natural history of the disease**

*Week 1 of illness*
Patients initially develop influenza-like prodromal symptoms. Presenting symptoms include fever, malaise, myalgia, headache, and rigors. No individual symptom or cluster of symptoms has proven specific. Although history of fever is the most frequently reported symptom, it may be absent on initial measurement.

*Week 2 of illness*
Cough (initially dry), dyspnoea and diarrhoea may be present in the first week but more commonly reported in the second week of illness. Severe cases develop rapidly progressing respiratory distress and oxygen desaturation with about 20% requiring intensive care. Up to 70% of the patients develop diarrhoea which has been described as large volume and watery without blood or mucus. Transmission occurs mainly during the second week of illness.

**Clinical outcomes**
Based on an analysis of data from Canada, China, Hong Kong SAR, Singapore, Viet Nam and the United States during the 2003 epidemic the case fatality ratio (CFR) of SARS is estimated to range from 0% to more than 50% depending on the age group affected and reporting centre, with an crude global CFR of approximately 9.6\%. Higher mortality has also been associated with male sex and presence of co-morbidity in various studies.

**Elderly and paediatric cases and SARS in pregnancy**

Atypical presentations such as afebrile illness or concurrent bacterial sepsis/pneumonia have been highlighted as a particular problem in the elderly. Underlying chronic conditions and their more frequent use of health facilities have both contributed to initially unrecognized nosocomial transmission events. SARS occurred less frequently and was observed to be a milder illness in the paediatric population. Known cases of SARS in pregnancy have suggested an increase in fetal loss in early pregnancy and maternal mortality in later pregnancy.

**Radiological findings**

Early chest radiograph or CT changes are observed in most of the patients as early as days 3-4 of illness in spite of the absence of respiratory signs. These typically show patchy consolidation starting with a unilateral peripheral lesion which progress to multiple lesions or ground glass appearance. Some lesions follow a shifting pattern. Features during the later stages have sometimes included spontaneous pneumothorax, pneumomediastinum, sub-pleural fibrosis and/or cystic changes.

**Haematological and biochemical findings**

There are no haematological or biochemical parameters specific for SARS; however, studies have consistently highlighted the following:

**Haematological findings**

Lymphopenia is common on presentation and progresses during the course of the illness. Sometimes thrombocytopenia and prolonged APTT are observed.

**Biochemical findings**

LDH is frequently high and some reports have suggested association with poor prognosis. ALT, AST and CPK elevation are less frequently reported. Abnormal serum electrolytes have also been reported on presentation or during hospitalization including hyponatraemia, hypokalaemia, hypomagnesaemia and hypocalcaemia.

---

Annex 3. Guidance regarding the diagnosis of SARS in the inter-epidemic period – A concern for all health-care workers (HCWs)

Making a diagnosis of SARS sufficiently early in the disease to implement effective infection control and public health measures will prove a challenge that requires all HCWs to always incorporate risk-based infection control measures in care provision. To prevent or interrupt SARS-CoV transmission all health facilities should ensure they are applying standard precautions at all times, with the adoption of additional transmission-based precautions for the investigation and management of individuals with an acute respiratory illness based on an assessment of the population risk of SARS at the local level and the individual risk of SARS.

This will only occur within a culture that treats infection prevention and control as everyone’s responsibility. All HCWs should be encouraged to consider the possibility of SARS in a patient under their care. If there are features suggestive of SARS then any concerns should be raised promptly and trigger risk-based infection control measures. There must be monitoring and feedback on this process.

The non-specific nature of the presentation of SARS could lead to concern being raised in a vast number of patients who will ultimately prove to have another diagnosis. In practice, concern about the possibility of SARS may often be expressed at the stage where atypical pneumonia is suspected.

This process should not rely wholly on clinicians but should be responsive to the concerns raised by other HCWs.

Concern of SARS raised by clinicians
For clinicians the process of diagnosis from initial concern to confirmation or exclusion of a SARS diagnosis (see case description) is usually an incremental one following sequential information gathering from various sources that include:

- Clinical history
- Clinical examination
- Epidemiological information obtained from the individual, the health facility or the community
- Bedside monitoring
- Radiology investigations
- Haematology investigations
- Biochemistry investigations
- Microbiology and virology investigations
- Response to treatment
Concern about SARS raised by other health professionals

Concerns regarding SARS may be raised by any HCW. All HCWs need to ensure they are fully aware of what constitutes a clinical concern about SARS and how, in the course of their duties they could be involved in the presentation, investigation or treatment of an unrecognized SARS case.

They should be encouraged to raise concerns with both the clinicians and infection control team who should provide monitoring and feedback on the process.

Some examples are given:

- Infection control staff e.g. noting an increase in hospital acquired pneumonias
- Nursing staff e.g. noting a pattern of deterioration in a patient suggestive of SARS
- Staff involved in care of the elderly e.g. noting an increase in severe illness
- Occupational health staff e.g. noting staff sickness compatible with atypical pneumonia
- Physiotherapists e.g. noting a pattern of atypical pneumonia
- Radiographers e.g. noting a pattern of atypical pneumonia
- Radiologists e.g. noting a pattern of atypical pneumonia
- Haematologists e.g. noting a profile consistent with atypical pneumonia
- Biochemists e.g. noting a profile consistent with atypical pneumonia
- Microbiologists e.g. noting an increase in uncharacterised pneumonias
- Virologists e.g. noting an increase in requests for respiratory investigations
- Pharmacists e.g. noting an increase in prescribing for pneumonia

Atypical pneumonia

Common bacteria, such as *Streptococcus pneumoniae* and *Haemophilus influenzae* cause so-called "typical pneumonia". Cases of typical pneumonia present with fever, respiratory symptoms (cough, which is usually early in the illness and often productive, shortness of breath etc.), elevated white cell count and well-defined changes on the chest radiograph. They tend to respond to antibiotic therapy for community-acquired pneumonia.

In contrast, "atypical pneumonia" is defined as pneumonia or lower respiratory tract infection with an atypical presentation often with a gradual onset of symptoms such as non-productive, dry cough, a variable white blood cell count and chest radiograph changes. These include: patchy, poorly defined changes, which may be often more severe than the clinical picture would suggest. The causative agents include *Mycoplasma pneumoniae*, *Chlamydia* species, *Legionella pneumophila*, and *Coxiella burnetii*. 
Diagnosis of atypical pneumonia is in itself challenging but will be assisted by careful clinical assessment (including non-respiratory symptoms), and given the likely absence of auscultatory signs, accurate measurement of respiratory rate and oxygen saturation (where available). Chest radiography is of great use in achieving diagnosis and should be considered even in the absence of respiratory signs.
<table>
<thead>
<tr>
<th>SARS</th>
<th>Example</th>
<th>Caution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical history</td>
<td>Sudden onset of flu-like prodrome, fever, dry cough, non-respiratory symptoms e.g. diarrhoea, myalgia, headache and chills/rigors.</td>
<td>Take a travel history, occupational history, history of hospitalization and history of contact with healthcare facility or person with SARS. The absence of any of these factors in the history should not automatically exclude the diagnosis of SARS.</td>
</tr>
<tr>
<td>Clinical examination</td>
<td>Does not correlate with chest radiology changes</td>
<td>Lack of respiratory signs particularly in groups such as the elderly.</td>
</tr>
<tr>
<td>Bedside monitoring</td>
<td>Hypoxia</td>
<td>Temperature may not be elevated on admission. The respiratory rate should be documented.</td>
</tr>
<tr>
<td>Haematology investigations</td>
<td>Low lymphocyte count, raised C-reactive protein, prolonged activated partial thromboplastin time.</td>
<td>These changes are non-specific and are not always seen in SARS.</td>
</tr>
<tr>
<td>Biochemistry investigations</td>
<td>Raised lactate dehydrogenase, hepatic transaminases, creatine phosphokinase.</td>
<td>These changes are non-specific and are not always seen in SARS.</td>
</tr>
<tr>
<td>Radiology investigations</td>
<td>CXR changes poorly defined, patchy, progressive changes.</td>
<td>May present as a lobar pneumonia. Pneumothorax and pneumomediastinum may also occur.</td>
</tr>
<tr>
<td>Microbiology investigations</td>
<td>Investigate for community acquired and hospital-acquired pneumonias including atypical pneumonias.</td>
<td>Concurrent infections may occur.</td>
</tr>
<tr>
<td>Virology investigations</td>
<td>Investigate for other causes of atypical pneumonia</td>
<td>Interpret SARS-CoV test results with caution, based on the assessment of the population risk of SARS at the local level and the individual risk of SARS.</td>
</tr>
<tr>
<td>Treatment</td>
<td>Lack of response to antibiotic treatment for community-acquired pneumonia, including atypical pneumonia.</td>
<td>All viral pneumonias and a number of bacterial pneumonias will not respond to standard antibiotic treatments. As yet there is no proven treatment for SARS; supportive measures are recommended.</td>
</tr>
</tbody>
</table>
Annex 4: Algorithm for the management of returning travellers from countries affected by avian influenza presenting with febrile respiratory illness

Algorithm for the management of returning travellers from countries affected by avian influenza presenting with febrile respiratory illness

1 Screening
(e.g. at triage station, by telephone or a GP surgery)
Clinical: Fever and respiratory symptoms OR other severe life-threatening illness
AND
Epidemiological: Travel in the last 2 weeks to countries affected by avian influenza or Health Care Worker (HCW) who has been in contact with a case of severe unexplained respiratory illness

2 Assessment
Initial medical/nursing assessment
(e.g. in side room, by telephone, in GP surgery or at home)
Clinical: Fever ≥ 38°C OR history of fever AND respiratory symptoms (cough or shortness of breath)
AND
Epidemiological: Within 7 days of onset of symptoms, travel to one of the following: Cambodia, China, (including Tibet and Hong Kong), Indonesia, Japan, Kazakhstan, Laos, Russia, Thailand, or Vietnam AND close contact (within 1 metre) with live or dead domestic fowl, wild birds, or swine in any setting
OR Close contact with other case(s) of severe respiratory illness or unexplained death from above areas
OR Part of H5N1 cluster (≤ 2 cases) of severe unexplained respiratory illness
OR Laboratory worker with potential exposure to influenza A (H5N1)

3 Reassessment
Specialist assessment / reassessment at 48 hours
No alternative diagnosis within 48 hours
AND CXR consistent with avian influenza
AND Clinical course consistent with avian influenza

Infection Control & Reporting
Take Infection Control Precautions
Hospital Location: Side room
Patients to wear mask (surgical)
Staff to wear respirator mask – minimum standard FFP2, gown and gloves
Strict hand hygiene
Primary care / community Location: At patient’s home in private
Patients to wear mask (surgical)
Staff to wear mask, gown and gloves
Strict hand hygiene

Inform Director of Public Health
Inform hospital infection control & occupational health
Strict Respiratory Infection Precautions
 Patients: Strict respiratory isolation preferably in negative pressure room
*Staff: Correctly fitted high filtration mask – minimum standard FFP2, gown, gloves and eye protection

Lishe with Department of Public Health again

1. Interim guidelines on the investigation and management of suspected human cases of HPA (Influenza A(H5N1)) see www.hpsc.ie/DiseasesTopics/AvianInfluenza/InformationForHealthProfessionals/1181.pdf
2. Includes the possibility of a long incubation and late presentation
3. For current zones see www.who.int
4. For infection control advice see www.hpsc.ie/DiseasesTopics/AvianInfluenza/InformationForHealthProfessionals/1180.pdf
5. Please check HPSC website www.hpsc.ie for further updates.

HSE-HPSC Version 1.0 August 2005. Adapted with permission from material produced by HPA
ANNEX 5: TESTING For SARS IN THE INTEREPIDEMIC PERIOD

Figure 1. Testing and reporting algorithm for SARS in the inter-epidemic period

See 2.3 ‘The laboratory diagnosis of SARS’ and 2.5 ‘Laboratory case definition for SARS’ for the tests and quality assurance required for the confirmation of SARS.
ANNEX 6: TESTING For SARS DURING AN OUTBREAK

Figure 2. Testing and reporting algorithm for SARS during an outbreak

**INDIVIDUAL WITH CLINICAL EVIDENCE FOR SARS**

*Independently verified at a WHO SARS Verification and Reference Laboratory
OR
*‘Preliminary positive’ at a national health authority-designated SARS laboratory

Yes

Tests -ve

Discard

No

At least one case in >1 chain of transmission previously confirmed by a WHO SARS Verification and Reference Laboratory

Follow testing and reporting algorithm for the interepidemic period

SARS Alert in a previously SARS – free country or area

Lost to follow-up, or deceased with neither autopsy nor laboratory tests performed

Yes

Is epidemiologically linked to a verified chain of transmission

Manage as SARS until epidemiological and/or laboratory evidence supports the diagnosis or the patient is discarded as a case of SARS

No

‘Confirmed’ case

‘Probable’ case

Unverifiable’ case

Has a single positive SARS antibody test, or a positive RT-PCR from a single clinical sample or assay at a national health authority designated SARS laboratory

Yes

No

Tests -ve

Discard

Updated HCP SARS Guidance Final Version August 22 2005

Page 37 of 38
* See 2.3 ‘The laboratory diagnosis of SARS’ and 2.5 ‘Laboratory case definition for SARS’ for the tests and quality assurance required for the confirmation of SARS.